Tibotec Virco-Virology announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the approval of Incivo (telaprevir), a direct acting antiviral for the treatment of chronic genotype-1 hepatitis C virus (HCV), in combination with pegylated-interferon and ribavirin, the previously accepted standard of care.
iStockAnalyst